Gemfibrozil Tablet
Product Images NDC 68788-7964

This appears to be a list of side effects and symptoms associated with the use of a medication or drug. The medication may have caused weight loss, heart palpitations, liver dysfunction, dizziness, confusion, and musculoskeletal discomfort. Additionally, it may have caused changes in libido, mood, and vision. Some individuals may have experienced allergic reactions or skin irritations. It is uncertain whether there is a causal relationship between the medication and these symptoms.*

This text presents a comparison between the frequency of adverse events reported by a group of 2046 subjects treated with gemfibrozil and another group of 2035 subjects who received a placebo. It lists the adverse events reported, with their frequency in percentage, for each group. The adverse events reported in the gemfibrozil group were generally more frequent than in the placebo group, but most events did not have a significant difference between groups. The adverse events reported included gastrointestinal reactions, dyspepsia, abdominal pain, appendicitis, and atrial fibrillation. Other common adverse events reported by more than 1% of subjects included diarrhea, fatigue, nausea/vomiting, eczema, rash, vertigo, constipation, and headache.*

Generic for Lopid 600mg tablet contains 600mg of Gemfibrozil, an oral medication used to lower cholesterol and triglycerides in the blood. The tablet is manufactured by Camber Pharmaceuticals and has a red cautionary statement regarding the prohibition of transfer under federal law. The dosage strength is USP 600mg and can be used to treat hyperlipidemia and hypertriglyceridemia. Each container has a lot number and manufacturing date mentioned on it.*

The text describes a table showing the reduction in coronary heart disease rates in patients based on their baseline lipid levels from the Helsinki Heart Study. The table includes data for all patients with different HDL and TG levels as well as LDL-C levels above 175. It also shows the incidence of events and the difference in rates between the placebo and gemfibrozil groups. The events considered are a combination of fatal and non-fatal myocardial infarctions and sudden cardiac deaths over a 5-year period.*

The table shows the occurrence of cardiac events and all-cause mortality per 1000 patients during the 3.5 year open-label follow-up to the Helsinki Heart Study. The data is presented for six groups based on original randomization and drug taken during follow-up. The number of patients in each group is also provided.*

The Table Il shows the comparison between Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study for the years 0-8.5, using Gemfibrozil and Placebo. The intention-to-treat analysis was conducted on the patients randomized originally, ignoring open-label treatment switches and exposure to study conditions. The table displays the event numbers, Hazard Ratio, and the 95% confidence intervals for the gemfibrozil: placebo group. The Gemfibrozil group shows a lower risk of Cardiac events and a higher risk of Non-Cardiac Deaths compared to the Placebo group. However, there is no significant difference between the groups in terms of Cardiac Deaths and All-Cause Mortality. The study includes fatal and non-fatal myocardial infarctions plus sudden cardiac deaths over the 8.5 year period.*